                         SEQUENCE LISTING

<110>  Queen Mary University of London
 
<120>  Method

<130>  P102078PCT

<150>  GB 1311031.7
<151>  2013-06-20

<160>  44    

<170>  PatentIn version 3.5

<210>  1
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  C-terminal alpha-helix sequence


<220>
<221>  misc_feature
<222>  (7)..(8)
<223>  Xaa can be any naturally occurring amino acid

<220>
<221>  misc_feature
<222>  (13)..(13)
<223>  Xaa can be any naturally occurring amino acid

<220>
<221>  misc_feature
<222>  (16)..(16)
<223>  Xaa can be any naturally occurring amino acid

<220>
<221>  misc_feature
<222>  (20)..(20)
<223>  Xaa can be any naturally occurring amino acid

<220>
<221>  misc_feature
<222>  (23)..(23)
<223>  Xaa can be any naturally occurring amino acid

<400>  1

Glu Pro Arg Gly Asp Leu Xaa Xaa Leu Ala Ala Arg Xaa Lys Arg Xaa 
1               5                   10                  15      


Phe Asn Glu Xaa Leu Ala Xaa Leu Gln Glu Lys Gly Ile 
            20                  25                  


<210>  2
<211>  30
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  3(10)-helix sequence


<220>
<221>  misc_feature
<222>  (7)..(8)
<223>  Xaa can be any naturally occurring amino acid

<220>
<221>  misc_feature
<222>  (12)..(12)
<223>  Xaa can be any naturally occurring amino acid

<220>
<221>  misc_feature
<222>  (15)..(15)
<223>  Xaa can be any naturally occurring amino acid

<220>
<221>  misc_feature
<222>  (18)..(18)
<223>  Xaa can be any naturally occurring amino acid

<220>
<221>  misc_feature
<222>  (21)..(21)
<223>  Xaa can be any naturally occurring amino acid

<220>
<221>  misc_feature
<222>  (24)..(24)
<223>  Xaa can be any naturally occurring amino acid

<400>  2

Glu Pro Arg Gly Asp Leu Xaa Xaa Leu Ala Ala Xaa Leu Lys Xaa Glu 
1               5                   10                  15      


Phe Xaa Glu Asn Xaa Leu Ala Xaa Leu Gln Glu Lys Gly Ile 
            20                  25                  30  


<210>  3
<211>  20
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  A20 FMDV ligand sequence

<400>  3

Asn Ala Val Pro Asn Leu Arg Gly Asp Leu Gln Val Leu Ala Gln Lys 
1               5                   10                  15      


Val Ala Arg Thr 
            20  


<210>  4
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide sequence comprising RGD motif followed by a C-terminal 
       3(10)-helix


<220>
<221>  misc_feature
<222>  (5)..(6)
<223>  Xaa can be any naturally occurring amino acid

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa can be any naturally occurring amino acid

<220>
<221>  misc_feature
<222>  (13)..(13)
<223>  Xaa can be any naturally occurring amino acid

<220>
<221>  misc_feature
<222>  (16)..(16)
<223>  Xaa can be any naturally occurring amino acid

<220>
<221>  misc_feature
<222>  (19)..(19)
<223>  Xaa can be any naturally occurring amino acid

<220>
<221>  misc_feature
<222>  (22)..(22)
<223>  Xaa can be any naturally occurring amino acid

<400>  4

Arg Gly Asp Leu Xaa Xaa Leu Ala Ala Xaa Leu Lys Xaa Glu Phe Xaa 
1               5                   10                  15      


Glu Asn Xaa Leu Ala Xaa 
            20          


<210>  5
<211>  21
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide sequence comprising RGD motif followed by a C-terminal 
       alpha-helix


<220>
<221>  misc_feature
<222>  (5)..(6)
<223>  Xaa can be any naturally occurring amino acid

<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  Xaa can be any naturally occurring amino acid

<220>
<221>  misc_feature
<222>  (14)..(14)
<223>  Xaa can be any naturally occurring amino acid

<220>
<221>  misc_feature
<222>  (18)..(18)
<223>  Xaa can be any naturally occurring amino acid

<220>
<221>  misc_feature
<222>  (21)..(21)
<223>  Xaa can be any naturally occurring amino acid

<400>  5

Arg Gly Asp Leu Xaa Xaa Leu Ala Ala Arg Xaa Lys Arg Xaa Phe Asn 
1               5                   10                  15      


Glu Xaa Leu Ala Xaa 
            20      


<210>  6
<211>  30
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide sequence comprising RGD motif followed by a C-terminal 
       alpha-helix or 3(10)-helix

<400>  6

Gln Pro Arg Gly Asp Leu Thr Ser Leu Ala Ala Thr Leu Lys Thr Glu 
1               5                   10                  15      


Phe Met Glu Asn Thr Leu Pro Arg Leu Gln Glu Lys Gly Ile 
            20                  25                  30  


<210>  7
<211>  30
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide sequence comprising RGD motif followed by a C-terminal 
       alpha-helix or 3(10)-helix

<400>  7

Glu Pro Arg Gly Asp Leu Gln Arg Leu Ala Ala Arg Ile Asn Pro Val 
1               5                   10                  15      


Phe Gln Arg Asp Ala Ser Pro Arg Leu Gln Glu Lys Gly Ile 
            20                  25                  30  


<210>  8
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide sequence comprising RGD motif followed by a C-terminal 
       alpha-helix or 3(10)-helix

<400>  8

Gln Pro Arg Gly Asp Leu Gln Asp Leu Ala Ala Arg Asn Lys Arg Thr 
1               5                   10                  15      


Phe Asn Glu Ser Leu Ala Arg Leu Gln Glu Lys Gly Ile 
            20                  25                  


<210>  9
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide sequence comprising RGD motif followed by a C-terminal 
       alpha-helix or 3(10)-helix

<400>  9

Gln Pro Arg Gly Asp Leu Lys Gly Leu Gln Glu Lys Gly Ile 
1               5                   10                  


<210>  10
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide sequence comprising RGD motif followed by a C-terminal 
       alpha-helix or 3(10)-helix

<400>  10

Glu Pro Arg Gly Asp Leu Arg Asn Leu Ala Ala Arg Val Lys Arg Glu 
1               5                   10                  15      


Phe Asn Glu Asn Leu Ala Ala Leu Gln Glu Lys Gly Ile 
            20                  25                  


<210>  11
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide sequence comprising RGD motif followed by a C-terminal 
       alpha-helix or 3(10)-helix

<400>  11

Gln Pro Arg Gly Asp Leu His Leu Leu Ala Ala Arg Ser Lys Pro Gly 
1               5                   10                  15      


Ser Asn Glu Met Leu Ala Thr Leu Gln Glu Lys Gly Ile 
            20                  25                  


<210>  12
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide sequence comprising RGD motif followed by a C-terminal 
       alpha-helix or 3(10)-helix

<400>  12

Gln Pro Arg Gly Asp Leu His Met Leu Ala Ala Arg Ala Lys Arg His 
1               5                   10                  15      


Phe Asn Glu Met Leu Ala Thr Leu Gln Glu Lys Gly Ile 
            20                  25                  


<210>  13
<211>  30
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide sequence comprising RGD motif followed by a C-terminal 
       alpha-helix or 3(10)-helix

<400>  13

Glu Pro Arg Gly Asp Leu Gln Met Leu Ala Ala Arg Leu Lys Lys Glu 
1               5                   10                  15      


Phe Thr Glu Asn Gln Leu Ala Pro Leu Gln Glu Lys Gly Ile 
            20                  25                  30  


<210>  14
<211>  30
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide sequence comprising RGD motif followed by a C-terminal 
       alpha-helix or 3(10)-helix

<400>  14

Gln Pro Arg Gly Asp Leu Thr Ser Leu Ala Ala Thr Leu Lys Thr Glu 
1               5                   10                  15      


Phe Met Glu Asn Thr Leu Pro Arg Leu Gln Glu Lys Gly Ile 
            20                  25                  30  


<210>  15
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide sequence comprising RGD motif followed by a C-terminal 
       alpha-helix or 3(10)-helix

<400>  15

Gln Pro Arg Gly Asp Leu Ala Ser Leu Ala Pro Arg Pro Lys Pro Phe 
1               5                   10                  15      


Phe Asn Glu Thr Leu Ala Ser Leu Gln Glu Lys Gly Ile 
            20                  25                  


<210>  16
<211>  30
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide sequence comprising RGD motif followed by a C-terminal 
       alpha-helix or 3(10)-helix

<400>  16

Glu Pro Arg Gly Asp Leu Ser Ser Leu Ala Ala Arg Thr Lys Pro Gly 
1               5                   10                  15      


Val Gln Pro Ala Ala Leu Ala Thr Leu Gln Glu Lys Gly Ile 
            20                  25                  30  


<210>  17
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide sequence comprising RGD motif followed by a C-terminal 
       alpha-helix or 3(10)-helix

<400>  17

Glu Pro Arg Gly Asp Leu Gln Ile Leu Ala Thr Pro Glu Arg Thr Gly 
1               5                   10                  15      


Leu Ser Thr Leu Gln Glu Lys Gly Ile 
            20                  25  


<210>  18
<211>  32
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide sequence comprising RGD motif followed by a C-terminal 
       alpha-helix or 3(10)-helix

<400>  18

Ser Ala Arg Glu Pro Arg Gly Asp Leu Ser Pro Leu Ala Ala Arg Ala 
1               5                   10                  15      


Lys Arg Glu Phe Asn Glu Asn Leu Ala Asn Leu Gln Glu Lys Gly Ile 
            20                  25                  30          


<210>  19
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide sequence comprising RGD motif followed by a C-terminal 
       alpha-helix or 3(10)-helix

<400>  19

Gln Pro Arg Gly Asp Leu Gln Asp Leu Ala Ala Arg Asn Lys Arg Thr 
1               5                   10                  15      


Phe Asn Glu Ser Leu Ala Arg Leu Gln Glu Lys Gly Ile 
            20                  25                  


<210>  20
<211>  30
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide sequence comprising RGD motif followed by a C-terminal 
       alpha-helix or 3(10)-helix

<400>  20

Glu Pro Arg Gly Asp Leu Gln Arg Leu Ala Ala Arg Ile Asn Pro Val 
1               5                   10                  15      


Phe Gln Arg Asp Ala Ser Pro Arg Leu Gln Glu Lys Gly Ile 
            20                  25                  30  


<210>  21
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide sequence comprising RGD motif followed by a C-terminal 
       alpha-helix or 3(10)-helix

<400>  21

Glu Pro Arg Gly Asp Leu Gln Ala Leu Ala Ala Arg Thr Lys Arg Asp 
1               5                   10                  15      


Phe Asn Glu Val Leu Pro Pro Leu Gln Glu Lys Gly Ile 
            20                  25                  


<210>  22
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide sequence comprising RGD motif followed by a C-terminal 
       alpha-helix or 3(10)-helix

<400>  22

Gln Pro Arg Gly Asp Leu Asp Ile Leu Ala Ala Arg Ile Lys Arg Asp 
1               5                   10                  15      


Phe Asn Gln Ser Leu Ala Ser Leu Gln Glu Lys Gly Ile 
            20                  25                  


<210>  23
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide sequence comprising RGD motif followed by a C-terminal 
       alpha-helix or 3(10)-helix

<400>  23

Glu Pro Arg Gly Asp Leu Arg Thr Leu Ala Ala Arg Glu Lys Arg Asn 
1               5                   10                  15      


Phe Asn Glu Thr Leu Ala Arg Leu Gln Glu Lys Gly Ile 
            20                  25                  


<210>  24
<211>  30
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide sequence comprising RGD motif followed by a C-terminal 
       alpha-helix or 3(10)-helix

<400>  24

Glu Pro Arg Gly Asp Leu His Ser Leu Ala Ala Arg Thr Lys Arg Gly 
1               5                   10                  15      


Phe Asn Glu Lys Arg Leu Ala His Leu Gln Glu Lys Gly Ile 
            20                  25                  30  


<210>  25
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide sequence comprising RGD motif followed by a C-terminal 
       alpha-helix or 3(10)-helix

<400>  25

Glu Pro Arg Gly Asp Leu Gln Ser Leu Ala Ser Pro Thr Leu Gln Glu 
1               5                   10                  15      


Lys Gly Ile 
            


<210>  26
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide sequence comprising RGD motif followed by a C-terminal 
       alpha-helix or 3(10)-helix

<400>  26

Gln Pro Arg Gly Asp Leu His Val Leu Ala Ser Pro Pro Leu Gln Glu 
1               5                   10                  15      


Lys Gly Ile 
            


<210>  27
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide sequence comprising RGD motif followed by a C-terminal 
       alpha-helix or 3(10)-helix

<400>  27

Glu Pro Arg Gly Asp Leu Ser Arg Leu Ala Ala Arg Ser Lys Arg Asp 
1               5                   10                  15      


Phe Asn Gln Glu Leu Ala Ala Leu Gln Glu Lys Gly Ile 
            20                  25                  


<210>  28
<211>  20
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide sequence comprising RGD motif followed by a C-terminal 
       alpha-helix or 3(10)-helix

<400>  28

Glu Pro Arg Gly Asp Leu His Gln Leu Ala Ala Arg Ser Lys Leu Gln 
1               5                   10                  15      


Glu Lys Gly Ile 
            20  


<210>  29
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide sequence comprising RGD motif followed by a C-terminal 
       alpha-helix or 3(10)-helix

<400>  29

Gln Pro Arg Gly Asp Leu Ser Ser Leu Ala Pro Arg Gly Lys Pro Asp 
1               5                   10                  15      


Phe Asn Glu Thr Leu Ala Arg Leu Gln Glu Lys Gly Ile 
            20                  25                  


<210>  30
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide sequence comprising RGD motif followed by a C-terminal 
       alpha-helix or 3(10)-helix

<400>  30

Glu Pro Arg Gly Asp Leu Trp Gln Leu Ala Ala Arg Trp Lys Arg Pro 
1               5                   10                  15      


Ser Thr Ser Ser Leu Ala Met Leu Gln Glu Lys Gly Ile 
            20                  25                  


<210>  31
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide sequence comprising RGD motif followed by a C-terminal 
       alpha-helix or 3(10)-helix

<400>  31

Gln Pro Arg Gly Asp Leu Arg Glu Leu Ala Ala Arg Ser Glu Ala Gln 
1               5                   10                  15      


Leu Gln Glu Lys Gly Ile 
            20          


<210>  32
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide sequence comprising RGD motif followed by a C-terminal 
       alpha-helix or 3(10)-helix

<400>  32

Glu Pro Arg Gly Asp Leu Ala Ser Leu Ala Ala Arg Tyr Lys Pro Glu 
1               5                   10                  15      


Phe Asn Glu Gln Leu Ala Tyr Leu Gln Glu Lys Gly Ile 
            20                  25                  


<210>  33
<211>  30
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide sequence comprising RGD motif followed by a C-terminal 
       alpha-helix or 3(10)-helix

<400>  33

Glu Pro Arg Gly Asp Leu Gln Met Leu Ala Ala Arg Leu Lys Lys Glu 
1               5                   10                  15      


Phe Thr Glu Asn Gln Leu Ala Pro Leu Gln Glu Lys Gly Ile 
            20                  25                  30  


<210>  34
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  C-terminal capping motif

<400>  34

Leu Gln Glu Lys Gly Ile 
1               5       


<210>  35
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  alpha-helix sequence


<220>
<221>  misc_feature
<222>  (2)..(3)
<223>  Xaa can be any naturally occurring amino acid

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa can be any naturally occurring amino acid

<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  Xaa can be any naturally occurring amino acid

<220>
<221>  misc_feature
<222>  (15)..(15)
<223>  Xaa can be any naturally occurring amino acid

<400>  35

Leu Xaa Xaa Leu Ala Ala Arg Xaa Lys Arg Xaa Phe Asn Glu Xaa Leu 
1               5                   10                  15      


<210>  36
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  alpha-helix sequence


<220>
<221>  misc_feature
<222>  (2)..(3)
<223>  Xaa can be any naturally occurring amino acid

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa can be any naturally occurring amino acid

<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  Xaa can be any naturally occurring amino acid

<220>
<221>  misc_feature
<222>  (15)..(15)
<223>  Xaa can be any naturally occurring amino acid

<400>  36

Leu Xaa Xaa Leu Ala Ala Arg Xaa Lys Arg Xaa Phe Asn Glu Xaa Leu 
1               5                   10                  15      


Ala 
    


<210>  37
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide motif


<220>
<221>  misc_feature
<222>  (5)..(6)
<223>  Xaa can be any naturally occurring amino acid

<400>  37

Arg Gly Asp Leu Xaa Xaa Leu 
1               5           


<210>  38
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Alpha-helix donor sequence

<400>  38

Leu Ala Arg Leu Lys Arg Glu Phe Asn Glu 
1               5                   10  


<210>  39
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Sequence motif


<220>
<221>  misc_feature
<222>  (2)..(3)
<223>  Xaa can be any naturally occurring amino acid

<400>  39

Leu Xaa Xaa Leu Leu 
1               5   


<210>  40
<211>  117
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Primer 2/alpha-helix


<220>
<221>  misc_feature
<222>  (23)..(24)
<223>  n is a, c, g, or t

<220>
<221>  misc_feature
<222>  (32)..(33)
<223>  n is a, c, g, or t

<220>
<221>  misc_feature
<222>  (44)..(45)
<223>  n is a, c, g, or t

<220>
<221>  misc_feature
<222>  (53)..(54)
<223>  n is a, c, g, or t

<220>
<221>  misc_feature
<222>  (68)..(69)
<223>  n is a, c, g, or t

<220>
<221>  misc_feature
<222>  (71)..(72)
<223>  n is a, c, g, or t

<400>  40
ccagatccct ttctcctgca amnnggctag mnnctcgttg aamnnccgct tmnntcgggc       60

tgcgagmnnm nntaggtctc ctcgaggttc tcttgcacag taatacacgg ccgtgtc         117


<210>  41
<211>  120
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Primer 2/310-helix


<220>
<221>  misc_feature
<222>  (23)..(24)
<223>  n is a, c, g, or t

<220>
<221>  misc_feature
<222>  (32)..(33)
<223>  n is a, c, g, or t

<220>
<221>  misc_feature
<222>  (41)..(42)
<223>  n is a, c, g, or t

<220>
<221>  misc_feature
<222>  (50)..(51)
<223>  n is a, c, g, or t

<220>
<221>  misc_feature
<222>  (59)..(60)
<223>  n is a, c, g, or t

<220>
<221>  misc_feature
<222>  (71)..(72)
<223>  n is a, c, g, or t

<220>
<221>  misc_feature
<222>  (74)..(75)
<223>  n is a, c, g, or t

<400>  41
ccagatccct ttctcctgca amnncgcgag mnngttctcm nngaactcmn ncttcagmnn       60

ggctgcgagm nnmnntaggt ctcctcgagg ttctcttgca cagtaataca cggccgtgtc      120


<210>  42
<211>  69
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Primer 3

<400>  42
gcctgaaccg cctccaccac tcgagacggt gaccagggta ccttggcccc agatcccttt       60

ctcctgcaa                                                               69


<210>  43
<211>  17
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Primer Fdseq

<400>  43
gaattttctg tatgagg                                                      17


<210>  44
<211>  17
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Primer LMB3

<400>  44
caggaaacag ctatgac                                                      17


